J Wood & Assoc

Jonathan Wood & Associates, An MDedge Hem/Onc Co. | 12th T-Cell Lymphoma Forum 30-JAN to 1-Feb 2020 | La Jolla, CA |

[J Wood & Assoc @JWood_Assoc]

The T-Cell Lymphoma Forum begins today! Don't miss Dr Jim Armitage deliver his keynote address today 5pm ET "Management of Patients With PTCL: A Paradigm For Clinical Research" #tcellforum21

[MedscapeLIVE @MedscapeLIVE]

The 13th annual T-Cell lymphoma Forum begins on July 8th. Register here to learn about the most relevant topics in relation to hematology and oncology. #TCellForum21

Register now https://t.co/FTsOWm4c4D

[MedscapeLIVE @MedscapeLIVE]

The 13th annual T-Cell lymphoma Forum begins on July 8th. Register here to learn about the most relevant topics in relation to hematology and oncology. #TCellForum21

Register now https://t.co/lZTa3nxoQ0

[MedscapeLIVE @MedscapeLIVE]

#TCellForum21 kicks off at 7am PT, with expert perspectives on new therapies for peripheral t-cell lymphoma.

Register here https://t.co/VonisfR9SL

[MedscapeLIVE @MedscapeLIVE]

👏 #IIDSpring21 has raised more than $71,000 for @AADskin Camp Discovery + @WomensDerm!

📌 Register now for this innovative #dermatology conference, kicking off Tuesday 3/16. https://t.co/2rUu2Bjc01

#DermTwitter #DermPath

[J Wood & Assoc @JWood_Assoc]

Abstract submission deadline Nov 4! Submit for poster/oral presentation @ T-Cell Lymphoma Forum 2020 https://t.co/8gjKbQXCOz

[J Wood & Assoc @JWood_Assoc]

TCLF Call for abstracts! Submit your abstract by 11/4 for poster and oral presentation #tcell #lymphoma https://t.co/T74HbulKXE

[J Wood & Assoc @JWood_Assoc]

TCLF Call for abstracts! Submit your abstract by 11/4 for poster and oral presentation #tcell #lymphoma https://t.co/T74HbulKXE

[J Wood & Assoc @JWood_Assoc]

REGISTER NOW! 12th Annual T-Cell Lymphoma Forum https://t.co/xsWXh6pIEr

[MDedge Hematology & Oncology @MDedgeHemOnc]

Blood & Cancer Podcast: In this week’s episode David L. Streiner, PhD, discussed P values with @davidhenrymd, & @ilanayurkiewicz explores how quickly cancer can turn into bankruptcy.
Web: https://t.co/3rSk305pRa
Google: https://t.co/Gv6nHNalsv
Apple: https://t.co/2j9RyurcKp

[MDedge Hematology & Oncology @MDedgeHemOnc]

Scientists at the National Cancer Institute have described a new immunotherapy approach, which completely reversed tumors in a woman with advanced metastatic breast cancer. #forbes https://t.co/W7oQTtPVNi

[MDedge Hematology & Oncology @MDedgeHemOnc]

|Blood & Cancer #Podcast|
Emergency Oncology: Immunotherapy side effects in the ED
Web: https://t.co/3rSk305pRa
Google: https://t.co/Gv6nHNalsv
Apple: https://t.co/2j9RyurcKp
https://t.co/1qSs5WF3aH

[Jennifer Smith @notthatjensmith]

The PSEN1 inhibitor MRK-560 can target NOTCH1-mutant T-ALL, according to preclinical research. MRK-560 decreased proliferation in T-ALL cell lines and reduced #leukemia burden and increased survival in mouse models of NOTCH1-mutant T-ALL. #leusm https://t.co/kSRSRDEDjI

[MDedge Hematology & Oncology @MDedgeHemOnc]

Stop by and meet MDedge Blood & Cancer host @davidhenrymd at #ASCO19 on Sunday, June 2nd. Dr. Henry will be located at booth #4116 from noon to 1:00 pm for a meet-and-greet and to answer questions. @MDEdgeTweets

[Simon Rule @rule_simon]

Always good to have your research nurses bringing you back down to earth !

[Jennifer Smith @notthatjensmith]

#Lenalidomide reduced the risk of progression from #smolderingmyeloma to multiple #myeloma in a phase 2/3 trial to be presented at #ASCO19 as abstract 8001: https://t.co/cyTnJVbN50. #mmsm
All ASCO abstracts now available: https://t.co/uENxdWgl30

[Jennifer Smith @notthatjensmith]

It's exciting that this patient achieved #HIV remission after undergoing #HSCT for #Hodgkinlymphoma, but I wish media outlets had been more careful with the term "cure." An 18-month remission after stopping ART is really promising, but "cure" is a loaded word.

[Jennifer Smith @notthatjensmith]

Madan Jagasia reports "clinically meaningful" responses in phase 2 study of #KD025 in #cGVHD. #TCTM19

[Muzaffar Qazilbash @Transplant_Doc]

#TCTM19 Dr. Locke on prevention and management of FDA-approved CAR-T cell therapy. He also compared Zuma-1 results with the standard of care experience #tcellrx

[Jennifer Smith @notthatjensmith]

Data suggest the incidence of #drug-related AEs decreased by 28% from 2014 to 2017, post-op #VTEs decreased by 17%, #CLABSIs by decreased by 6%, and overall #HACs decreased by 13%